HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.

A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have shown delay or prevention of viral rebound following ant...

Full description

Bibliographic Details

Published in:	PLoS Pathogens
Main Authors:	Brian Moldt, Abishek Chandrashekar, Erica N Borducchi, Joseph P Nkolola, Heather Stephenson, Mark Nagel, Magdeleine Hung, Joshua Goldsmith, Craig S Pace, Brian Carr, Nathan D Thomsen, Wade S Blair, Romas Geleziunas, Dan H Barouch
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-04-01
Online Access:	https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010467&type=printable